Compare Equinox Gold Corp. Common Shares (EQX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinox Gold Corp. Common Shares vs Organon & Co. Common Stock — how do they compare? Equinox Gold Corp. Common Shares trades at $10.43 (market cap $12.62B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Equinox Gold Corp. Common Shares is far larger — about 3.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Equinox Gold Corp. Common Shares for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| EQX | OGN | |
|---|---|---|
Market Cap | $12.62B | $3.62B |
Volume | 12,370,191 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $18.76 | $13.81 |
52-Week Low | $8.62 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.72B | $11.04B |
Dividend Yield | 0.48% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinox Gold (EQX) trades at $10.85, down 3.12% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $1.82B revenue and $221M net income, and projects significant growth in 2026 to $2.9B revenue. Recent news highlights the completion of the Orla Mining merger, positioning EQX as a major North American gold producer with a path to 2 million ounces of annual production.
The outlook is positive due to transformative growth from the Orla acquisition, increased production guidance, and a 50% dividend hike. Risks include execution of mine expansions and gold price volatility. With a 100% buy rating from one analyst, the stock appears undervalued relative to its growth pipeline, though recent earnings misses warrant monitoring.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equinox Gold Corp. Common Shares
Equinox Gold is a gold mining company with operations in the Americas. It produces gold and develops additional mining projects.
Read more on EQX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
